Objectives: this study aimed to determine the prevalence of hepatitis B virus (HBV) coinfection and HBV seropositivity in perinatally HIVinfected adolescents. A secondary objective was to describe the clinical characteristics of adolescents with chronic HBV/HIV coinfection. Materials and Methods: Multicenter cross-sectional study of perinatally HIV-infected adolescents aged 12-25 years. HBV surface antigen, surface antibody (anti-HBs) and core antibody (anti-HBc) were measured. Coinfection was defined as having persistently positive HBV surface antigen. seroprotective antibody from immunization was defined as having anti-HBs ≥10 mIU/mL with negative anti-HBc. HBV DNA quantitation and rtM204V/I mutation analysis (lamivudine resistance-associated mutation) were performed in adolescents with chronic HBV infection. Results: From November 2010 to March 2011, 521 patients were enrolled. Mean (sD) of CD4 lymphocyte count was 685 (324) cells/μL. the prevalence of HBV/HIV coinfection was 3.3% (95% confidence interval: 1.9-5.2%). protective antibody against HBV was found in 18% of population, and this was significantly higher among adolescents who received than those who did not receive HBV revaccination after receiving antiretroviral therapy (93% versus 6%, P < 0.01). Among adolescents with chronic HBV infection, 88% have received lamivudine; however, 69% have HBV DNA >10 5 copies/mL and 75% had the rtM204V/I mutation. Conclusions: the prevalence of HBV coinfection in HIV-infected thai adolescents was 3.3%. Most HIV-infected adolescents had no HBV protective antibody; therefore, revaccination with HBV vaccine is encouraged. the high prevalence of HBV-lamivudine resistance underscores the importance of HBV screening prior to antiretroviral therapy initiation to guide the selection of optimal regimen for coinfected children.
A n estimated 350 million people worldwide are chronically infected with hepatitis B virus (HBV). 1 Among HIV-infected populations, HBV is more prevalent due to overlapping transmission routes: perinatal, percutaneous contact with body fluid and sexual exposure. the risk of developing chronic HBV infection after acute exposure ranges from 90% in newborns of hepatitis B e antigen-positive mothers to 25-30% in infants and children <5 years and to <5% in adults. 2 HIV infection greatly affects the clinical course of HBV infection. 3 patients with coinfection have higher HBV DNA levels, a decreased likelihood of HBV clearance, which leads to a higher chance of developing chronic HBV infection ranging from 10% to 15%, 4 and higher rates of HBV-associated liver disease. 5 several reverse transcriptase inhibitors, such as lamivudine (3tC) and tenofovir disoproxil fumarate (tDF), have activity against both HIV and HBV, making therapeutic decisions more complicated. treating HIV infection without knowing patients' HBV infection status might lead to the selection of HBV-resistant mutants, and treating HBV infection without knowing patients' HIV infection status might lead to the selection of HIV-resistant mutants. 6 the prevalence of HIV-HBV coinfection is reported to be 8.7-10% among HIV-infected adults in Asia 7, 8 and 4.9% among HIV-infected children in China. 9 As of 2010, the incidence of HBV infection in thailand was only 8.4 per 10,000 people due to high coverage of immunization during childhood. 10 However, there has been no routine HBV screening program among HIV-infected children in thailand. HBV-HIV coinfection becomes an important issue when HIV-infected children become adolescents, when HBV can enter a period of immune activation and when HBV drug resistance may develop after prolonged use of antiretroviral therapy (Art) that contains only 1 drug (3tC) active against HBV.
this study aimed to determine the prevalence of HBV coinfection and protective HBV antibody in perinatally HIV-infected adolescents. the secondary objective was to describe the clinical characteristics of adolescents with chronic HBV/HIV coinfection.
MATERIALS AND METHODS
A cross-sectional study was conducted at 4 
Laboratory Measurements
HBV status was determined by serologic testing, which included HBV surface antigen (HBsAg), HBV surface antibody (anti-HBs) and HBV core antibody (anti-HBc). HBsAg detection was performed by microparticle enzyme immunoassay, enzymelinked immunosorbent assay test or immunochemiluminescence. Anti-HBs and anti-HBc were measured using the Abbott AxSYM System (Wiesbaden, Germany), enzyme-linked immunosorbent assay or immunochemiluminescence.
HBV-HIV coinfection was defined as persistent positive HBsAg on at least 2 occasions at least 6 months apart, resolved natural infection was defined as having both positive anti-HBc and anti-HBs ≥10 mIU/mL and seroprotective antibody from immunization was defined as having anti-HBs ≥10 mIU/mL with negative anti-HBc. 11 Children with HBV-HIV coinfection had a second blood drawn to test for the presence of hepatitis B e antigen (HBeAg), hepatitis B e antibody (anti-HBe), HBV DNA level and 3TC resistance mutation (change in rtM204I, the YMDD motif, to either YVDD or YIDD). HBeAg and anti-HBe were measured by Abbott AxSYM, microparticle enzymatic immunoassay at the HIV-Netherlands-Australia-Thailand Research Collaboration laboratory.
HBV DNA was measured by a real-time PCR assay with a limit of detection of 100 copies/mL. 12, 13 To pinpoint the change in the YMDD motif, HBV nucleotides were translated into amino acid sequences using the translation tool in ExPASy Proteomics Server (available at: http//www.expasy.ch/tools/dna.html). HBV genotype was determined by comparing with each complete HBV genome sequences. Phylogenetic analysis was constructed by Molecular Evolutionary Genetics Analysis (MEGA) software version 3.1.
13
HBV mutation analysis assessed the presence of rtM204V/I by pinpointing the change in the YMDD motif; HBV nucleotides were translated into amino acid sequences using the translation tool provided by the ExPASy Proteomics Server (available at: http:// www.expasy.ch/tools/dna.html) 14 at the Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University. The whole genome HBV sequences obtained from this study were submitted to the GenBank database with the accession no. JN827414-JN827425. Alanine aminotransferase was considered elevated using a cutoff >30 IU/L.
15

Statistical Analysis
The prevalence of HBV-HIV coinfection, resolved natural infection and HBV seroprotection were reported as a proportion with 95% confidence intervals (CIs). The χ 2 test or Fisher's exact and logistic regression analysis were used to make comparisons between groups. All analyses were performed using the Statistical Package for Social Science version 17.0 software (SPSS Inc., Chicago, IL).
RESULTS
From November 2010 to March 2011, 521 patients were enrolled; 227 (44%) were male; their mean age (SD) was 14.8 (2.1) years. All cases were perinatally HIV-infected except for 1 case acquired from blood transfusion and 1 case acquired from sexual abuse. Only 15 adolescents (3%) were born before the implementation of routine HBV immunization in Thailand in 1992. The mean current CD4 lymphocyte count (SD) was 685 (324) cells/µL and 86% had HIV RNA level (viral load) <400 copies/mL, which met the criterion of HIV viral suppression. HBV vaccination during childhood was reported or documented for 281 (54%) cases. Seventy-four of 521 adolescents (14%) had received a 3-dose HBV revaccination after immune recovery as a result of ART, which included 20 (22%) and 54 (52%) of adolescents from The HIV Netherlands, Australia, Thailand Research Collaboration and Research Institute for Health Sciences, Chiang Mai University site, respectively. The median time between revaccination and blood draw for this study was 4.3 (interquartile range 3.7-4.5) years. Risk factors for HBV acquisition other than perinatal transmission were blood transfusion in 10 cases (2%) and history of engaging in sexual activity in 40 cases (8%). HBV infection status stratified by study site is shown in Table 1 . Seventeen children were HBV/HIV coinfected (3.3%; 95% CI: 1.9-5.2%). There was no difference in chronic HBV infection rate by gender (3.7% among females and 2.6% among males, P = 0.62). A comparison of characteristics among those with and without HBV coinfection is shown in Table 2 . Among 15 cases born before 1992, 1 case (6.7%) had positive HBsAg and 1 (6.7%) had resolved natural infection. Three of those who had hepatitis B revaccination after 5 copies/mL. Only 2 cases had HBV DNA <100 copies/mL; 1 was currently treated with 3TC and TDF. HBeAg was presented in 14/16 cases (88%), whereas anti-HBe was presented in only 1/16 (6%) cases. Anti-HBc could not be detected in 4 cases. There were 6 participants (35%) with elevated alanine aminotransferase >30 IU/L. Current antiretroviral drugs included 3TC (88%) and TDF (12%). Resistance to 3TC was detected in 9 of 12 cases tested (75%).
Resolved natural infection was found in 8 cases (1.5%; 95% CI: 0-3%). None of them had documented or recalled a history of clinical hepatitis. Isolated core antibody (anti-HBc) was detected in 4 cases (0.8%; 95% CI: 0-2%). Ninety-six cases (18%) had protective antibody against HBV with a significantly higher proportion found among adolescents who received HBV revaccination after receiving ART (93% versus 6%; P < 0.01). The characteristics of participants with and without protective antibody against hepatitis B are shown in Table 4 . The group with protective antibody had higher mean age, higher CD4 lymphocyte count and a higher proportion with history of immunization against HBV.
DISCUSSION
The prevalence of HBV/HIV coinfection is 3.3% in perinatally HIV-infected Thai adolescents receiving ART. Approximately 70% of adolescents with HBV coinfection had high HBV DNA and 3TC resistance-associated mutations. Only 18% of adolescents had protective antibody against HBV.
The prevalence of HBV coinfection in our study was higher than that reported among a non-HIV-infected, healthy Thai population. The national expanded program for immunization included 3 doses of HBV vaccine for all children at birth, 2 and 6 months of age since 1992. Data from a countrywide HBsAg seroprevalence survey conducted in 2004 showed a prevalence of 4.4% and 0.82% among those who were born before 1992 and after 1992, respectively. 16 Almost all (97%) participants in our study were born after universal hepatitis immunization was implemented in Thailand, providing evidence that hepatitis B infection is more prevalent in HIV-infected Thai children.
The Thai program for universal HBV immunization beginning at birth may explain the lower HIV-HBV coinfection prevalence in our study when compared with what has been reported in other Asian and African countries. A Chinese study demonstrated HBV coinfection among 4.9% of children with a median age of History of blood transfusion, no (%) 3 (18) 37 (7) 0.134 Sexually active by self-report, no (%) 1 (6) 31 (6) 1.000 7 years. 9 HBsAg seroprevalence in our study was slightly lower, whereas the prevalence of HBV carriers in general population was similar at around 10%. 7, 8 A Nigerian study reported a 7.7% prevalence of HIV/HBV coinfection in HIV-infected children aged 10 months to 17 years, whereas the prevalence in Nigerian adults ranged from 7.5% to 44.7%. 17 Studies in HIV-infected Kenyan children aged 0-12.7 years (2003) and Tanzanian children aged <2 to >15 years (2006) have reported positive HBsAg in 4% and 1.2%, respectively. 18, 19 The 4 adolescents with HBV-HIV coinfection but negative anti-HBc in our cohort likely had false-negative anti-HBc results, because HBV DNA was detected in 3 of 4 cases. All of them had HIV virologic suppression and good immune status with current CD4 lymphocyte count ranging from 376 to 583 cells/µL.
We found isolated core antibody in 4 cases (0.8%); none had HBV DNA detected. This was interpreted as resolved natural infection without generation of protective antibody response or with the initial antibody response that subsequently waned. All of them were female, with an age range (12.2-15.9 years) similar to the overall age of participants in this cohort. An adult HIV study in Taiwan where HBV infection was hyperendemic reported the prevalence of isolated anti-HBc as 17.5%, with HBV DNA detectable in 8.3% of those patients. The authors suggested that this might be related to old age and low CD4 lymphocyte count. 20 A US study observed that individuals coinfected with HIV and hepatitis C virus were more likely to have isolated core antibody (anti-HBc) than HIV-infected individuals without hepatitis C infection 21 ; they claimed that it was associated with the severity of immune suppression. Low CD4 lymphocyte counts were not a clear factor in our 4 cases (CD4 lymphocyte counts in 260-1327 cells/µL), but we had too few cases to evaluate predictors for isolated core antibody.
Low hepatitis B seroprotective antibody rates (18%) in this study might be due to primary vaccine failure or waning of immunity during the period of immunosuppression prior to antiretroviral initiation. The P1024US study also reported that 24% of HIV-infected children receiving ART were hepatitis B seropositive. 22 Revaccination with hepatitis B vaccine may therefore be needed in this population. We have previously reported that 92% of HIV-infected children with immune recovery after ART had HBV seroconversion after revaccination with a 3-dose recombinant HBV vaccine. 23 Furthermore, the protective antibody against HBV lasted for 3 years after revaccination in 71% of children receiving stable antiretroviral treatment with immune recovery. 24 In the current study, 75% of children had HBV-3TC-associated mutations. This is in line with a previous report that 3TC monotherapy is associated with a high risk of developing the M204V resistance mutation, at a rate of approximately 20-25% per year. 25, 26 In our study, the median duration of antiretroviral drug therapy was 7 years. The HBV DNA levels in our study were very high: 69% of children had >10 5 copies/mL. 3TC monotherapy in patients was less likely to suppress HBV DNA <3 log 10 copies/mL at week 48 compared with those who received TDF plus 3TC (46% versus 92%). 27 Thus, we propose that HIV adolescents with HBV coinfection should receive combination therapy with TDF plus 3TC similar to that recommended in the adult population. 28 There are some study limitations to be addressed. First, we did not have a history of maternal HBV status and information on access to hepatitis B immunoglobulin, which are the main factors influencing HBV transmission risk. Second, we conducted our study at tertiary care hospitals, which may represent a group of participants with different characteristics than those who received HIV care at local hospitals.
The strength of this study comes from the systematic screening for hepatitis B coinfection in perinatally HIV-infected adolescents conducted in 4 sites, which represent adolescents surviving with HIV in different parts of the country. In addition, we confirmed chronic HBV infection by testing for HBV DNA.
